Menu
Your Cart

EGFR ELISA Kit

EGFR ELISA Kit
EGFR ELISA Kit
  • Stock: In Stock
$680.00

Available Options

Description

EGFR ELISA Kit 

Catalog Number: EGFR-01-1152

Size: 1 plate (96 wells)

EGFR ELISA Kit is a sandwich enzyme-linked immunoassay for the quantitative determination of EGFR with high sensitivity and specificity in serum or plasma.

   

Kit Performance

  • Sensitivity: 30 pg/mL
  • Assay Range: 30 – 500 pg/mL
  • Cross-reactivity: There is no cross reaction with native immunoglobulins
  • Recovery rate: 80 – 120% with normal human serum or plasma samples with known concentrations.
  • Precision

(CV (%) = SD/mean X 100)

  • Intra-Assay: CV < 20%
  • Inter-Assay: CV < 20%

Materials Supplied

List of component

Components

  Quantity

High binding Plate

  1 plate

EGFR

  1 µg

10x Capture

  700 µL

10x Detection

  700 µL

1x Streptavidin (HRP) (Avoid light)

  12 mL

1x Plate Coating Buffer

  15 mL

1x Blocking Buffer

  15 mL

2x Assay Diluent

  30 mL

1x TMB Substrate (Avoid light)

  12 mL

1x Stop Solution

  12 mL

 

Storage Instruction

The components arrive with ice pack, and must immediately be stored at 2-8°C. The kit components are stable at the date specified in CoA.

 

Supplementary information

Epidermal Growth Factor Receptor (EGFR) is a transmembrane receptor tyrosine kinase that regulates key cellular processes such as proliferation, survival, and differentiation.

EGFR consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular tyrosine kinase domain. When ligands such as epidermal growth factor bind to the receptor, EGFR undergoes dimerization and activates its kinase activity. This leads to phosphorylation of tyrosine residues on the receptor, creating docking sites for signaling proteins.

Activated EGFR initiates several downstream signaling pathways, most notably the RAS–RAF–MAPK/ERK pathway, which promotes cell proliferation, and the PI3K–AKT pathway, which supports cell survival and metabolism. Through these pathways, EGFR signaling regulates gene expression and cellular responses to growth signals.

Because of its role in tumor development, EGFR has become an important therapeutic target. Targeted therapies include small-molecule tyrosine kinase inhibitors that block EGFR kinase activity and monoclonal antibodies that prevent receptor activation. EGFR mutation or expression status is therefore often used as a predictive biomarker to guide treatment selection.